Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

Inclusion Criteria: * Men and women between ages 18 - 65 years who have suffered from palmoplantar pustulosis (PPP) for at least 6 months. * Patients were required to have over 10 well-demarcated white or yellow pustules across all regions, with or without plaque psoriasis * Patients were required to have a Palmoplantar Pustular Physician's Global Assessment (PPPGA) score of at least moderate severity (≥3) and a minimum PPPASI score of 12. * Signed and dated written informed consent in accordance with ICH GCP and local legislation prior to admission to the trial. * Further criteria apply. Exclusion Criteria: * Systemic treatment for PPP ended less than five half-lives or 12 weeks ago * Topical treatment for PPP ended less 4 weeks ago * Women who are pregnant, nursing, or who plan to become pregnant while in the trial. * Severe, progressive, or uncontrolled condition such as renal, hepatic, haematological, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms thereof. * Presence or known history of anti-TNF-induced PPP-like disease. * Patient with a transplanted organ (with exception of a corneal transplant \>12 weeks Prior to screening) or who have ever received stem cell therapy. * Known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly. * Further criteria apply.